Bluejay Diagnostics (BJDX) Accumulated Expenses (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 506.22% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 506.22% YoY), and the FY2025 full-year result was $804942.0, up 45.83% from the prior year.
• Accumulated Expenses grew to $1.1 million in Q1 2026, from $804942.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.9 million in Q3 2023 to a low of $143449.0 in Q3 2024.
• A 5-year average of $832089.9 and a median of $835730.0 in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 92.35% in 2024 and surged 506.22% in 2026, its largest moves.
• Tracing BJDX's Accumulated Expenses over 5 years: stood at $835730.0 in 2022, then soared by 33.64% to $1.1 million in 2023, then slumped by 50.58% to $551986.0 in 2024, then surged by 45.83% to $804942.0 in 2025, then soared by 36.23% to $1.1 million in 2026.
• Business Quant data shows BJDX's Accumulated Expenses at $1.1 million in Q1 2026, $804942.0 in Q4 2025, and $264513.0 in Q3 2025.